Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a downside of -2.08% to close Friday at $0.59 after subtracting -$0.01 on the day. The 5-day average trading volume is 16,485,439 shares of the company’s common stock. It has gained $0.6350 in the past week and touched a new high 1 time within the past 5 days. An average of 12,471,990 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 12,280,316.
TNXP’s 1-month performance is -18.96% or -$0.1377 on its low of $0.5750 reached on 09/30/21. The company’s shares have touched a 52-week low of $0.51 and high of $2.12, with the stock’s rally to the 52-week high happening on 02/11/21. YTD, TNXP has lost -12.80% or -$0.0864 and has reached a new high 9 times. However, the current price is down -72.24%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Tonix Pharmaceuticals Holding Corp. (TNXP) has a trailing price-to-earnings (P/E) ratio of 33.83 for the broader industry and 32.48 for the sector, meaning that investors are optimistic about the stock’s future prospects.TNXP stock has a beta of 1.25. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 1.09.
Tonix Pharmaceuticals Holding Corp.’s quick ratio for the period ended June 29 was 21.90, with the current ratio over the same period at 21.90 meaning that TNXP stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00.
For the quarterly period ending June 29 this year, Analysts expected TNXP to announce -$0.06 per share in earnings in its latest quarter, but it posted -$0.07, representing a -16.70% surprise. TNXP stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 8.67 million, with total debt at $1.05 million. Shareholders hold equity totaling $357.52 million
Let’s look briefly at Tonix Pharmaceuticals Holding Corp. (TNXP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 38.30% to suggest the stock is trending Neutral, with historical volatility in this time period at 46.07%.
The stock’s 5-day moving average is $0.5949, reflecting a -2.92% or -$0.0177 change from its current price. TNXP is currently trading -20.45% above its 20-day SMA, -43.40% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -41.72% and -1.08% respectively.
Stochastic %K and %D was 13.89% and 13.45% and the average true range (ATR) pointed at 0.0341. The RSI (14) points at 37.65%, while the 14-day stochastic is at 14.95% with the period’s ATR at 0.0365. The stock’s 9-day MACD Oscillator is pointing at -0.0115 and -0.0163 on the 14-day charts.
In the most recent analyst report for Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), ROTH Capital upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for TNXP stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate TNXP as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is TNXP’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $3.00 and a high of $3.00, with their median price target at $3.00. Looking at these predictions, the average price target given by analysts is for Tonix Pharmaceuticals Holding Corp. (TNXP) stock is $3.00.